Date
Title
View
25 Feb 22
Preliminary annual results as of 31 December 2021
29 Nov 21
Change of forecast for the financial year 2021
13 Jul 21
Preliminary half-year results as of 30.06.2021
29 Apr 21
Application for change from Prime Standard to General Standard
18 Feb 21
KROMI takeover offer will not be pursued further
30 Dec 20
4basebio AG announces changes to the Management Board
05 Oct 20
4basebio announces share capital reduction by way of reverse stock split
24 Sep 20
4basebio AG signs term sheet for investment in nanoparticle-based gene therapy delivery technology
17 Aug 20
4basebio AG announces process for spin-off and separate stock market listing for its DNA business
20 Apr 20
4basebio AG: 4basebio AG resolves on capital reduction by way of redemption of approx. 5.2 million treasury shares in accordance with the authorizing resolution of the general meeting
10 Feb 20
4basebio AG: 4basebio AG decides to increase the public share buyback offer volume from 2,056,452 to 5,230,726 shares
21 Jan 20
4basebio AG: 4basebio AG decides to buy back 2 million treasury shares for further use in accordance with the authorizing resolution